A part of Watch Media

MedWatchSaturday4 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
25/03/2022at 14:10

WS Audiology and GN settle false advertising case in US

Hearing aid firms WSA and GN Hearing-owned Lively have entered settlements with the Attorney General Connecticut Office. The firms had marketed products as “FDA-approved” when they were in fact only registered. ”An oversight,” a WSA representative calls it.
Photo: WS Audiology / PR
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

Hearing aid manufacturers WS Audiology and GN Hearing have been reprimanded by Connecticut Attorney General William Tong for having falsely marketed certain products in the US.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Gitte Aabo, CEO at GN Hearing | Photo: GN Hearing / PR

    GN Hearing left 9 percent ownership in Lively's hands to ensure work motivation

  • Photo: Eric Thayer/Reuters/Ritzau Scanpix

    WS Audiology halts IPO plans for subsidiary

    For subscribers

  • Eric Bernard, CEO of WS Audiology | Photo: WS Audiology / PR

    CEO of WSA: "Multi channel is the future"

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Foto: Thomas Borberg/Ritzau Scanpix
Medtech

Another hurdle overcome in delaying MDR deadline

EU member countries have voted unanimously to adopt an EU Commission proposal to stagger the implementation of the new Medical Device Regulation. Now, only the EU Parliament’s vote remains. 
  • Asensus Surgical wins CE Mark for intelligent surgical unit under MDR rules
  • EU Commission to give more time for MDR transition

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

For subscribers

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast's bottom line disappoints in otherwise strong report

For subscribers

Further reading

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Hearing health

Sonova launches competing product to GN's hybrid hearing device

The Swiss giant announces the launch of an early entry device for people with mild hearing loss, which could compete with GN Hearing’s Jabra Enhance Plus targeting the same group.

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Hearing health

Bank lowers Demant share target week before annual report

Jyske Bank says investors will want to pay attention next week to Demant’s 2023 outlook which is likely to contain cautious expectations for the year ahead.

For subscribers

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Foto: Viatris/PR.
Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

A market authorization application from US-based generics maker Viatris for a copy version of obesity treatment Wegovy breaches five of Novo Nordisk’s patents, claims the company in a lawsuit.

For subscribers

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Regulatory Affairs Professional

  • Senior Clinical Project Manager

  • Medical Advisor (Metabolism)

  • Experienced Patent Counsel

  • Commercial Director

  • Supply Chain Manager

  • Lead Data Architect

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Application Manager

  • Clinical Operational Associate

  • Application Manager

  • Sr. Director, Drug Safety Physician

See all jobs

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Regulatory Affairs Professional

  • Senior Clinical Project Manager

  • Medical Advisor (Metabolism)

  • Experienced Patent Counsel

  • Commercial Director

  • Supply Chain Manager

  • Lead Data Architect

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Application Manager

  • Clinical Operational Associate

  • Application Manager

  • Sr. Director, Drug Safety Physician

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge